Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Income from Continuing Operations (2016 - 2025)

IGC Pharma (IGC) has disclosed Income from Continuing Operations for 16 consecutive years, with 1821000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 6.06% to 1821000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 6446000.0, a 48.72% increase, with the full-year FY2025 number at 7121000.0, up 45.22% from a year prior.
  • Income from Continuing Operations was 1821000.0 for Q3 2025 at IGC Pharma, down from 1599000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1197000.0 in Q1 2025 to a low of 6503000.0 in Q1 2022.
  • A 5-year average of 2790105.26 and a median of 2381000.0 in 2021 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 162.16% in 2021, then skyrocketed 67.28% in 2024.
  • IGC Pharma's Income from Continuing Operations stood at 2381000.0 in 2021, then grew by 5.54% to 2249000.0 in 2022, then crashed by 148.51% to 5589000.0 in 2023, then surged by 67.28% to 1829000.0 in 2024, then rose by 0.44% to 1821000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Income from Continuing Operations are 1821000.0 (Q3 2025), 1599000.0 (Q2 2025), and 1197000.0 (Q1 2025).